EGFR K757R

CI-VAR-00002180Explore in graph →NP_005219.2:p.Lys757ArgNM_005228.3:c.2270A>GClinVar 560009 CIViC 723 rs397517102

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
EGFR K757R	Erlotinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID1786 In a meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, one patient was described with the exon 19 mutation K757R from the MERIT study. Progression-free (250 days) and overall (4… (full text at CIViC) PMID 26773740 · Klughammer et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
560009	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications	1	Lung adenocarcinoma; EGFR-related lung cancer; Hereditary cancer-predisposing syndrome	germline	3	Feb 03, 2026	clinvar